AEON Biopharma, Inc. Appoints John Bencich As Chief Financial Officer Ahead Of Key Regulatory Milestones

AEON Biopharma, Inc., a biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX with the goal of achieving accelerated and full-label U.S. market entry, announced the appointment of John Bencich as Chief Financial Officer. His arrival comes at a crucial time as AEON prepares for its next phase of regulatory progress and operational execution.

According to Rob Bancroft, President and Chief Executive Officer of AEON, John’s appointment marks an important advance for the company. He noted that Bencich’s experience leading finance teams at publicly traded biotechnology companies, along with his extensive capital markets expertise, will help strengthen AEON’s financial strategy, deepen relationships with institutional stakeholders, and support disciplined capital planning as the company moves through its regulatory pathway. He added that this leadership will be essential to creating long-term value.

Mr. Bencich shared that AEON is executing a focused and differentiated biosimilar strategy in a large therapeutic market with significant potential. He expressed confidence in the company’s opportunity to build a stronger financial foundation and support its next phase of growth. He also noted that joining AEON at this stage represents a meaningful opportunity to contribute to a turning point in the company’s evolution.

John Bencich brings over 25 years of experience across corporate strategy, capital market transactions, and business development for both emerging companies and publicly traded organizations. Most recently, he served as Chief Executive Officer of Achieve Life Sciences, where he led fundraising efforts, helped drive notable market capitalization growth, oversaw major clinical and regulatory achievements, strengthened the company’s intellectual property position, and advanced commercial planning and business development initiatives.

Earlier in his career, he held Chief Financial Officer roles at several organizations, including OncoGenex Pharmaceuticals, Integrated Diagnostics, Allozyne, and Trubion Pharmaceuticals. In these positions, he supported multiple financings, strategic transactions, and public-company readiness efforts. Mr. Bencich holds a Bachelor of Accountancy from the University of San Diego and an MBA from Seattle University.